Mois : avril 2021

Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique, Dr Christian SUEUR, GRECC, avril 2021

Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique Projet CBD Thérapeutique, GRECC. Dr Christian SUEUR, avril 2021. 93 pages   Aujourd’hui, il n’est plus tabou au plan international de penser et d’appliquer des prescriptions de cannabinoïdes en clinique psychiatrique et addictologique.[1] En France, lors de la première séance du C.S.S.T. « Évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis en France », le 12 décembre 2018, c’est « le membre psychiatre » du C.S.S.T., le docteur George Brousse lui-même, qui souhaitait d’emblée « que soit mentionnée l’utilisation potentielle du CBD dans les troubles psychiatriques et de l’addiction, tout en précisant que le [...]

Lire la suite

Un grand débat sur une politique de régulation des drogues, Fédération Addiction, publié le 19/04/2021

Un grand débat sur une politique de régulation des drogues publié le 19/04/2021  | Communiqué du 19 avril 2021 La Fédération Addiction appelle depuis longtemps à un grand débat sur la régulation des substances psychoactives tant en termes de santé que de sécurité. Le président de la République dresse le constat que « la France est devenue un pays de consommation ». La pénalisation de l’usage de drogues illégales n’a pourtant jamais été remise en cause depuis 51 ans, notre législation reste une des plus sévères et l’application des sanctions n’a cessé de se renforcer. Tout cela est parfaitement documenté par les travaux de l’OFDT et OEDT[1]. Sur la même période, prévention et réduction [...]

Lire la suite

Psilocybin Delivers ‘Remarkable’ Relief in Severe Depression, Batya Swift Yasgur, Medscape.com, 2020

Psilocybin Delivers 'Remarkable' Relief in Severe Depression Batya Swift Yasgur, MA, LSW Medscape Medical News, November 05, 2020   Psilocybin, the psychedelic compound in "magic mushrooms," rapidly improves symptoms and produces remission in as little as two sessions for patients with major depression, new research suggests. Results of a small randomized trial showed that treatment with psilocybin was associated with a greater than 50% reduction in depressive symptoms in 67% of study participants. In addition, 71% showed improvement at 4-week follow-up, with more than 50% achieving remission. "The finding that the majority of people whom we treated showed efficacy was quite a remarkable and gratifying finding [...]

Lire la suite

Psilocybin Matches SSRI for Moderate-to-Severe Depression in Phase 2 Study, Sarah Edmonds, 2021

Psilocybin Matches SSRI for Moderate-to-Severe Depression in Phase 2 Study Sarah Edmonds Medscape Medical News, April 14, 2021   The psychedelic drug psilocybin performed just as well as a widely used antidepressant in easing the symptoms of major depression, and outperformed the selective serotonin reuptake inhibitor (SSRI) on a range of secondary measures, results of a small-scale phase 2 study show. In a 6-week trial that included 59 patients with moderate-to-severe depression, there was no significant difference between the impact of high-dose psilocybin on the study's primary yardstick — the 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR-16) — and that of selective serotonin reuptake [...]

Lire la suite

‘Magic Mushrooms’ Effective for Severe Depression, Batya Swift Yasgur, medscape.com, 2017

'Magic Mushrooms' Effective for Severe Depression Batya Swift Yasgur, MA, LSW Medscape Medical News © 2017 October 20, 2017   Psilocybin, the psychoactive compound in “magic mushrooms,” is a promising intervention for patients with treatment-resistant depression (TRD) and appears to offer a rapid, sustained effect, new research shows. Investigators led by David Nutt, MD, PhD, professor of neuropsychopharmacology, Imperial College, London, United Kingdom, collected pre- and posttreatment fMRI data on the use of psilocybin in 19 patients with severe major depression who had failed to respond to conventional treatments. The patients experience dramatic improvements in depressive symptoms 1 day following treatment; close to half met criteria for full response at 5 [...]

Lire la suite

FDA Grants Psilocybin Second Breakthrough Therapy Designation for Resistant Depression, Megan Brooks, medscape.com, 2019

FDA Grants Psilocybin Second Breakthrough Therapy Designation for Resistant Depression Megan Brooks Medscape Medical News © 2019 November 25, 2019   The US Food and Drug Administration (FDA) has granted the Usona Institute breakthrough therapy designation for psilocybin for the treatment of major depressive disorder (MDD). This marks the second time the FDA has granted breakthrough designation for psilocybin, the psychoactive ingredient in "magic mushrooms." In October 2018, Compass Pathways received the designation to test the safety and efficacy of psilocybin-assisted therapy for treatment-resistant depression, as reported by Medscape Medical News. "The results from previous studies clearly demonstrate the remarkable potential for psilocybin as a treatment in MDD patients, which Usona is [...]

Lire la suite